ArticleMed (New York, N.Y.)2023
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.
Article in Med (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Reprogramming NOX4-associated ferro-aging with an iron-chelating senescent-cell-targeted therapy for intervertebral disc degeneration.Bioactive materials · 2027Article
- Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications.Cancer cell international · 2026Review
- Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review.Translational cancer research · 2026Review
- A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.International journal of molecular sciences · 2026Article
- Insights into ectodomain shedding as a novel target in natural killer cell-based immunotherapy for cancer.Frontiers in immunology · 2026Review
- Advances inFrontiers in immunology · 2026Article
- A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Methodological approach for allele-specific antibody responses to HEK-293T-based cell lines expressing single MHC class I chain-related gene B antigens.BMC molecular and cell biology · 2025Article
- iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors.Cell reports. Medicine · 2025Article
- An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding.Cell reports. Medicine · 2025Article
- Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy.Clinical & translational immunology · 2025Review
- Review
- Effect of plasma-induced oxidation on NK cell immune checkpoint ligands: A computational-experimental approach.Redox biology · 2024Article
- Natural killer cells in cancer immunotherapy.MedComm · 2024Review
- Review
- Development of NK cell-based cancer immunotherapies through receptor engineering.Cellular & molecular immunology · 2024Review
- Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy.International journal of molecular sciences · 2024Review
- Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.Journal for immunotherapy of cancer · 2024Article
- NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.Current hematologic malignancy reports · 2023Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe advent of chimeric antigen receptor (CAR) T cell therapies has transformed the treatment of hematological malignancies; however, broader therapeutic success of CAR T cells has been limited in solid tumors because of their frequently heterogeneous composition. Stress proteins in the MICA and MICB (MICA/B) family are broadly expressed by tumor cells following DNA damage but are rapidly shed to evade immune detection.
methodsWe have developed a novel CAR targeting the conserved α3 domain of MICA/B (3MICA/B CAR) and incorporated it into a multiplexed-engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell (3MICA/B CAR iNK) that expressed a shedding-resistant form of the CD16 Fc receptor to enable tumor recognition through two major targeting receptors.
findingsWe demonstrated that 3MICA/B CAR mitigates MICA/B shedding and inhibition via soluble MICA/B while simultaneously exhibiting antigen-specific anti-tumor reactivity across an expansive library of human cancer cell lines. Pre-clinical assessment of 3MICA/B CAR iNK cells demonstrated potent antigen-specific in vivo cytolytic activity against both solid and hematological xenograft models, which was further enhanced in combination with tumor-targeted therapeutic antibodies that activate the CD16 Fc receptor.
conclusionsOur work demonstrated 3MICA/B CAR iNK cells to be a promising multi-antigen-targeting cancer immunotherapy approach intended for solid tumors.
fundingFunded by Fate Therapeutics and NIH (R01CA238039).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.